41 completed, 5 terminated, 3 not yet recruiting, 2 unknown. 53 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 53 | Completed 41, Terminated 5, Not yet recruiting 3, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow Plaque Psoriasis: new trials by email Literature Review of Plaque Psoriasis trials Research Report on Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients Secukinumab 300mg s.c., Metformin, Placebo - Psoriasis, Plaque Psoriasis | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 186 | 2026-06-01 | 2026-03-25 |
| Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia vunakizumab and recaticimab., vunakizumab and placebo - Plaque Psoriasis | Phase 4 | Not yet recruiting | Xiangya Hospital of Central South University | 40 | 2026-01-20 | 2026-01-28 |
| Bimekizumab in Plaque Psoriasis Bimekizumab - Plaque Psoriasis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 60 | 2024-06-03 | 2026-04-20 |
| A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients Cetaphil - Plaque Psoriasis, Psoriasis | Phase 4 | Completed | Galderma R&D | 46 | 2024-04-08 | 2026-06-09 |
| Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis secukinumab, Methotrexate, Cyclosporin A - Plaque Psoriasis | Phase 4 | Not yet recruiting | Singapore General Hospital | 40 | 2024-01-01 | 2022-11-25 |
| A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India Ixekizumab - Plaque Psoriasis, Psoriatic Arthritis | Phase 4 | Completed | Eli Lilly and Company | 250 | 2023-06-27 | 2025-08-22 |
| Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis Humira (Adalimumab), SB5 (Adalimumab Biosimilar) - Plaque Psoriasis | Phase 4 | Completed | Samsung Bioepis Co., Ltd. | 371 | 2022-08-04 | 2023-05-25 |
| Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. Secukinumab Injection - Plaque Psoriasis | Phase 4 | Completed | Jinnah Postgraduate Medical Centre | 50 | 2021-07-05 | 2023-06-07 |
| Guselkumab Immunogenetics Guselkumab - Psoriasis Guttate, Plaque Psoriasis | Phase 4 | Completed | University of California, San Francisco | 17 | 2021-03-01 | 2026-06-23 |
| Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis LEXETTE 0.05% Topical Foam, Sorilux 0.005 % Topical Foam, Vehicle Foam - Plaque Psoriasis | Phase 4 | Unknown | Skin Sciences, PLLC | 30 | 2021-01-01 | 2020-11-20 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab Brodalumab, Placebo, Guselkumab - Plaque Psoriasis, Psoriasis Vulgaris | Phase 4 | Terminated | LEO Pharma | 113 | 2020-12-17 | 2025-03-14 |
| Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis Ixekizumab, Methotrexate, Cyclosporin A - Plaque Psoriasis | Phase 4 | Recruiting | Singapore General Hospital | 40 | 2020-12-10 | 2022-11-25 |
| Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis Duobrii® - Palmoplantar Psoriasis, Plaque Psoriasis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 22 | 2020-11-19 | 2023-10-27 |
| Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis Tildrakizumab - Plaque Psoriasis | Phase 4 | Terminated | Almirall, S.A. | 47 | 2020-01-29 | 2021-12-08 |
| Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) Tildrakizumab 100 mg Solution for Injection - Plaque Psoriasis | Phase 4 | Completed | Almirall, S.A. | 178 | 2019-12-17 | 2023-03-03 |
| Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Dimethyl fumarate (DMF) standard scheme, Dimethyl fumarate (DMF) simplified scheme, Tildrakizumab - Plaque Psoriasis | Phase 4 | Completed | Almirall, S.A. | 190 | 2019-09-04 | 2022-05-27 |
| Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis Halobetasol Topical Foam - Plaque Psoriasis | Phase 4 | Completed | Mayne Pharma International Pty Ltd | 24 | 2019-06-14 | 2023-07-06 |
| A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Ixekizumab, Guselkumab, Placebo - Plaque Psoriasis | Phase 4 | Completed | Eli Lilly and Company | 1027 | 2018-11-09 | 2020-07-28 |
| Pain Outcomes Following Intralesional Corticosteroid Injections Corticosteroid with lidocaine, Corticosteroid with normal saline - Keloid, Alopecia Areata | Phase 4 | Completed | Vanderbilt University Medical Center | 31 | 2018-10-01 | 2021-03-11 |
| Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Enstilar® foam, Vehicle foam - Plaque Psoriasis, Psoriasis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 25 | 2018-05-21 | 2021-01-20 |
Showing 20 of 53. Sign in to see all of them.
Psoriasis (12) · Plaque, Amyloid (2) · Acne Vulgaris (1) · Alopecia Areata (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Cicatrix, Hypertrophic (1) · Crohn Disease (1) · Dermoid Cyst (1) · Granuloma Annulare (1) · Guttate Psoriasis (1) · Keloid (1) · Keratoacanthoma (1) · Lichen Planus (1) · Neurodermatitis (1)
Skin and Connective Tissue Diseases (17) · Skin Diseases (15) · Skin Diseases, Papulosquamous (15) · Pathological Conditions, Signs and Symptoms (4) · Arthritis (2) · Connective Tissue Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathological Conditions, Anatomical (2) · Psoriasis (2) · Signs and Symptoms (2) · Acneiform Eruptions (1) · Alopecia (1)
secukinumab (7) · Etanercept (6) · betamethasone dipropionate, calcipotriol drug combination (5) · calcipotriene (4) · Acitretin (3) · apremilast (3) · guselkumab (3) · ixekizumab (3) · tildrakizumab (3) · Adalimumab (2) · Betamethasone (2) · Cyclosporine (2) · Methotrexate (2) · Adrenal Cortex Hormones (1) · Alefacept (1)
Galderma R&D (7) · Derm Research, PLLC (4) · Icahn School of Medicine at Mount Sinai (4) · Novartis Pharmaceuticals (4) · Almirall, S.A. (3) · Amgen (3) · Eli Lilly and Company (2) · Singapore General Hospital (2) · University of California, San Francisco (2) · Astellas Pharma Inc (1) · Dermatrials Research (1) · Innovaderm Research Inc. (1) · Jinnah Postgraduate Medical Centre (1) · L.H. Kircik, M.D. (1) · LEO Pharma (1)
United States (33) · Canada (9) · Germany (6) · Spain (6) · Italy (5) · Poland (5) · Belgium (4) · United Kingdom (4) · Bulgaria (3) · Czechia (3) · Greece (3) · Hungary (3) · Argentina (2) · Austria (2) · Denmark (2)
Ronald W Gottschalk, MD (3) · Ying Ying Leung, MD (2) · Adele R Clark, PA-C (1) · Alan B Fleischer, Jr, M.D. (1) · Alice Gottlieb, MD, PhD (1) · Andrew Alexis, MD, MPH (1) · Bernard S Goffe, MD (1) · Brian Drolet, MD (1) · Daniel J Piacquadio, MD (1) · Dr Shatrughan Sahay (1) · Dr Sudhakar Grandhi (1)
PMID 21386955, PMID 21455550, PMID 21877508, PMID 22106730, PMID 25913550, PMID 25994179, PMID 32880909, PMID 33760691, PMID 34273904, PMID 35279805, PMID 35305260, PMID 38300408, PMID 38332436, PMID 38521874, PMID 39332633, PMID 40255182, PMID 41774505, PMID 41881197, PMID 42191094
2019 (3), 2015 (2)